"Look to Take Advantage of the Recent Weakness" - Oppenheimer Bullish on PDS Biotechnology Corp (PDSB) In Face of Selloff Jun 8, 2022 05:54AM
Oppenheimer Reiterates Outperform Rating, $25 Price Target on PDS Biotechnology Corp (PDSB) May 12, 2022 06:15AM
Heron Therapeutics (HRTX) and Omeros (OMER) Top Cantor Fitzgerald's Most Shorted List; Amgen (AMGN) and PDS (PDSB) Seeing Biggest Increases Mar 10, 2022 05:45AM
Johnson & Johnson (JNJ), Cidara Therapeutics (CDTX), Pfizer (PFE), and PDS Biotechnology (PDSB) - Cantor Fitzgerald's Top Flu Vaccine Candidates for 2022 Feb 17, 2022 05:55AM
Oppenheimer Reiterates PDS Biotechnology (PDSB) at Outperform, "Broader Market Recovery Could be Particularly Supportive" for the Stock Feb 3, 2022 05:38AM